Evidence map›Paper›PMID 37122206›Full record

ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2023

Targeting p21-activated kinase 1 for development of a novel anti-arrhythmic drug class.

Yu He, Alexander Grassam-Rowe, Ming Lei, James S H Bae

Open access · hybridAbstract readReview
In one paragraph

Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Cardiomyocyte electrophysiology and its modulation: current views and future prospects.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yu HeDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Alexander Grassam-RoweDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Ming LeiDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.ORCID 0000-0002-0928-341X
James S H BaeDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.ORCID 0000-0002-1296-2640
University of Oxford · GB

Funding

British Heart Foundation FS/PHD/20/29053British Heart Foundation PG/12/21/29473British Heart Foundation PG/14/80/31106British Heart Foundation PG/16/67/32340British Heart Foundation PG/21/10512
6 · The paper itself

Abstract

Evidence accumulated over the past decade suggests that p21-activated kinase 1 (PAK1) is a critical cardiac-protective signalling molecule. The present article provides an updated review of recent findings regarding the role of PAK1 in maintaining normal cardiac electrophysiological function through its regulation of membrane and Ca

Indexed as

Anti-Arrhythmia Agentsp21-Activated KinasesCalciumCalcium-Calmodulin-Dependent Protein KinasesHeartPhosphorylationSarcoplasmic Reticulum Calcium-Transporting ATPasesAnti-Arrhythmia AgentsCalciumCalcium-Calmodulin-Dependent Protein Kinasesp21-Activated KinasesSarcoplasmic Reticulum Calcium-Transporting ATPasesarrhythmiaCa2+ clockFTY720membrane clockp21-activated kinase 1protein phosphatase 2A

Identifiers

PMID37122206
PMCPMC10150222
OpenAlexW4367600595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.